JADE COMPARE Analysis: Defining the Depth and Rapidity of Response of Abrocitinib and Dupilumab in Patients With Moderate to Severe Atopic Dermatitis

AAAAI February 26 - March 1, 2021, AAD VMX April 23-25, 2021; Virtual
Study suggests that treatment with abrocitinib 200 mg QD results in a greater and more rapid response vs dupilumab, as assessed using stringent endpoints.
Format: Microsoft PowerPoint (.ppt)
File Size: 455 KB
Released: June 15, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Incyte Corporation

Related Content

Assessment of antipruritic properties of ruxolitinib cream using pooled data from TRuE-AD1 and TRuE-AD2: atopic dermatitis conference coverage from Clinical Care Options (CCO)

Released: June 18, 2021

Characterization of skin pain in children with atopic dermatitis: atopic dermatitis conference coverage from Clinical Care Options (CCO)

Released: June 11, 2021

Analysis of efficacy of oral azoles as a potential treatment for dupilumab facial redness: atopic dermatitis conference coverage from Clinical Care Options (CCO)

Released: June 10, 2021

Interactive on-demand CCO Webcast featuring expert discussion on how new and emerging data in the management of atopic dermatitis will affect clinical practice

Andrew F. Alexis, MD, MPH Jonathan Silverberg, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Released: November 5, 2020 Expired: November 4, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue